Day One Biopharmaceuticals develops and sells precision medicines for cancer patients with genetic markers. Their Phase II clinical trial candidate DAY101 aims to treat pediatric patients with relapsed/progressive low-grade glioma using an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor. Additionally, they are working on Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.